Brentuximab vedotin after stem cell transplant for cutaneous T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of skin lymphoma called mycosis fungoides at stages IIB, III, IVA, or IVB.
- Your lymphoma cells express at least 1% of a protein called CD30.
- You have had at least one prior treatment that did not work or stopped working.
- Your lymphoma is currently partly or completely controlled (partial or complete response).
- You received a stem cell transplant from a related donor between 60 and 90 days ago.
- Your liver, kidney, and blood cell counts are within certain healthy ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted antibody-drug (brentuximab vedotin) plus standard chemotherapy (R-CHP) for people with a specific type of aggressive lymphoma that has a virus (EBV) in the tumor cells. The goal is to see if this combination works better than standard treatment.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests a combination of two drugs for people with a specific type of skin lymphoma. Brentuximab vedotin targets a protein called CD30 on lymphoma cells, and lisaftoclax helps destroy those cells. The goal is to see if this combination is safe and effective.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
Hear when a new Brentuximab Vedotin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.